Frederic Jacques de Bure

Direttore/Membro del Consiglio presso Inpellis, Inc.

52 anni

Consumer Services

Health Technology

Profilo

Frederic Jacques de Bure is an Independent Director at Inpellis, Inc. and a General Partner at Nusantara Ventures Singapore Pte Ltd.
He was previously a Non-Affiliated Director at PT Visi Media Asia Tbk.
Mr. de Bure holds an MBA from The University of Chicago and an undergraduate degree from Vassar College.

Posizioni attive di Frederic Jacques de Bure

Società	Posizione	Inizio
Nusantara Ventures Singapore Pte Ltd.	Corporate Officer/Principal	01/01/2009
Inpellis, Inc. Inpellis, Inc. Pharmaceuticals: MajorHealth Technology Inpellis, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing transdermal prescription therapeutics for treating acute and chronic pain resulting from musculoskeletal disorders and peripheral neuropathy. Its products include transdermal ibuprofen for moderate to severe osteoarthritis and transdermal benfotiamine for painful diabetic neuropathy. The company was founded in 2012 and is headquartered in Haddonfield, NJ.	Direttore/Membro del Consiglio	01/01/2015

Tutte le posizioni attive di Frederic Jacques de Bure

Precedenti posizioni note di Frederic Jacques de Bure

Società	Posizione	Fine
PT VISI MEDIA ASIA TBK	Corporate Officer/Principal	20/03/2012

Vedi nel dettaglio l'esperienza di Frederic Jacques de Bure

Formazione di Frederic Jacques de Bure

The University of Chicago	Masters Business Admin
Vassar College	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Frederic Jacques de Bure

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
PT VISI MEDIA ASIA TBK	Consumer Services

Aziende private	2
Nusantara Ventures Singapore Pte Ltd.
Inpellis, Inc. Inpellis, Inc. Pharmaceuticals: MajorHealth Technology Inpellis, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing transdermal prescription therapeutics for treating acute and chronic pain resulting from musculoskeletal disorders and peripheral neuropathy. Its products include transdermal ibuprofen for moderate to severe osteoarthritis and transdermal benfotiamine for painful diabetic neuropathy. The company was founded in 2012 and is headquartered in Haddonfield, NJ.	Health Technology